Abstract:Rare eye diseases encompass a broad spectrum of genetic anomalies with or without additional extraocular manifestations. Genetic eye disorders in pediatric patients often lead to severe visual impairments. Therefore, a challenge of gene therapy is to provide better vision to these affected children. In recent years, inherited retinal diseases, inherited optic neuropathies, and corneal dystrophies have dominated discussions to establish gene and cell replacement therapies for these diseases. Gene therapy involves the transfer of genetic material to remove, replace, repair, or introduce a gene, or to overexpress a protein, whose activity would have a therapeutic impact. For the majority of anterior segment diseases, these studies are still emerging at a preclinical stage; however, for inherited retinal disorders, translation has been reached, leading to the introduction of the first gene therapies into clinical practice. In the past decade, the first gene therapy for biallelic RPE65-mediated inherited retinal dystrophy has been developed and the FDA and EMA both approved ocular gene therapy. Other promising approaches by intravitreal injection have been investigated such as in CEP290-Leber congenital amaurosis. Various techniques of gene therapies include gene supplementation, CRISPR-based genome editing, as well as RNA modulation and optogenetics. Optogenetic therapies deliver light-activated ion channels to surviving retinal cell types in order to restore photosensitivity. Beyond retinal function, ataluren, a nonsense mutation suppression therapy, enables ribosomal read-through of mRNA containing premature termination codons, resulting in the production of a full-length protein. An ophthalmic formulation was recently evaluated with the aim of repairing corneal damage, pending new clinical studies. However, various congenital disorders exhibit severe developmental defects or cell loss at birth, limiting the potential for viral gene therapy. Therefore mutation-independent strategies seem promising for maintaining the survival of photoreceptors or for restoring visual function. Restoring vision in children with gene therapy continues to be a challenge in ophthalmology. © 2023 Published by Elsevier Masson SAS on behalf of French Society of Pediatrics.

Genetic Treatment Approaches in Rare Pediatric Diseases

Riding the gene therapy wave: challenges and opportunities for rare disease patients and clinicians

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord

Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases

Next-Generation Therapeutics for Rare Genetic Disorders

Somatic Gene Therapy Research in Pediatric Populations: Ethical Issues and Guidance for Operationalizing Early Phase Trials

CRISPR-Based Gene Editing Techniques in Pediatric Neurological Disorders

Gene and cell therapy of human genetic diseases: Recent advances and future directions

Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update

A new age of precision gene therapy

[Rare diseases: unraveling the biological bases to find future therapies]

Update on gene therapies in pediatric ophthalmology

Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations

Enhancing pediatric access to cell and gene therapies

Gene therapy and gene correction: targets, progress, and challenges for treating human diseases

Targeted treatment of solid tumors in pediatric precision oncology

Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies

Molecular Neurosurgery: Introduction to Gene Therapy and Clinical Applications

Novel gene therapies for sickle cell disease, Duchenne muscular dystrophy, and hemophilia A

Successes and challenges in clinical gene therapy